Australia’s First Class-Action Suits Against Merck’s Vioxx Set To Begin
This article was originally published in PharmAsia News
Long after Merck's anti-inflammatory Vioxx (rofecoxib) was pulled from the market, class-action suits against the company are getting under way in Australia's Federal Court. More than 1,000 people are expected to be represented in the first trials. Merck voluntarily recalled the drug in the United States in 2004 after it was linked to heart and stroke problems. More than 40,000 lawsuits have been filed, but Merck is contesting them in Australia. It settled U.S. suits for $5.2 million in 2007, but its Australia subsidiary, Merck Sharpe & Donne, has decided to challenge them. (Click here for more
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.